Updated on 22 May 2015
Toray Industries Inc. has received an approval for partial change to the manufacturing and marketing approval of Remitch Capsules 2.5 µg to include its new indication for improvement of pruritus in chronic liver disease patients in case of insufficient effectiveness of the treatment using existing drugs in Japan.
Toray already has manufacturing and marketing approval for Remitch Capsules 2.5 µg, which is being promoted and distributed by Torii Pharmaceutical as a treatment of pruritus in hemodialysis patients in the country.
Sumitomo Dainippon Pharma will provide drug information regarding the New Indication of Remitch Capsules 2.5 µg at medical institutions from May 20, 2015 in accordance with the promotion contract signed between Torii Pharmaceutical and Sumitomo Dainippon Pharma.
Toray will continue to supply Remitch Capsules 2.5 µg to Torii Pharmaceutical, which will distribute it and provide the drug information regarding the treatment of pruritus in hemodialysis patients to medical institutions.
The three companies expect that the approval of Remitch Capsules' New Indication would significantly contribute to the treatment of pruritus in chronic liver disease patients by offering a new treatment option.